Psychedelic Research Recap February 2024

What happens if psychedelics become a regular part of therapy? In a way, that is what the majority of research on psychedelics is trying to answer. Studies analysing the safety, to mapping out the effectiveness in various domains, including those featured here in February, help us understand psychedelics as medicines.

Blossom Pro: Research Briefing #5 – Microdosing for ADHD, PAT in Switzerland, and Repeated Psilocybin Dosing

How can microdosing support people who experience ADHD, and does it work better than conventional medications? The first article explores this across two studies. We then venture into the heart of Europe, where psychedelic-assisted psychotherapy has been legally possible for the last decade (again). Finally, I’ll focus on the flexible repeated dosing in a trial with psilocybin for depression.

Psychedelic Research Recap January 2024

January saw new psychedelic trials on ibogaine for TBI, DMT, and psilocybin for CCHs, alongside re-analyses on psychedelic brain impacts, therapy dynamics in MDMA treatment, and LSD visuals. Studies also probed SSRI-psychedelic interactions, expectancy roles, and heart effects from microdosing.

Psychedelic Research Links 2024

This link page serves as a centralized overview of psychedelic research studies published in 2024 that are not featured with individual pages in our database.